Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Lumasiran for Primary Hyperoxaluria Type 1: Analysis of Urinary Oxalate and eGFR Over Time in Patients With and Without Baseline Pyridoxine Use

Final Results from a Phase 1/2, 48-Month, Open-Label Extension Study of Givosiran in Patients with Acute Intermittent Porphyria

Long-term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Final Analysis of the ILLUMINATE-A Trial

Outpatient Heart Failure Worsening in Patients with Cardiac Transthyretin Amyloidosis: Results from the APOLLO-B Trial

Long-term treatment with lumasiran: final results from the phase 2 open-label extension study

RNAi Therapy in ATTRv Amyloidosis with Polyneuropathy (HELIOS-A): Patient-reported Experiences and Preferences

Effect of RNAi Therapeutics Patisiran and Vutrisiran on Orthostatic Hypotension Due to Dysautonomia in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyria: 36-Month Results of the Phase 3 ENVISION Randomized Clinical Trial

Effectiveness of Patisiran Following Switch From Tafamidis for the Treatment of Hereditary Transthyretin Mediated (hATTR) Amyloidosis with Polyneuropathy

Alnylam Act®: Effectiveness of Genetic Testing in Establishing a Diagnosis in Patients with Suspicion of Hereditary Transthyretin Amyloidosis

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.